Log in

NYSEAMERICAN:ASTAsterias Biotherapeutics Stock Price, Forecast & News

$0.0020
0.00 (0.00 %)
(As of 07/10/2019)
Add
Compare
Today's Range
$0.00
Now: $0.00
$0.00
50-Day Range N/A
52-Week Range
$0.51
Now: $0.00
$2.05
Volume1,000 shs
Average Volume136,653 shs
Market Capitalization$111,318.00
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Asterias Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing cell-based therapeutics to treat neurological conditions associated with demyelination, and cellular immunotherapies to treat cancer. Its clinical stage programs include AST-OPC1, an oligodendrocyte progenitor cell population derived from pluripotent stem cells that is in Phase I/IIa clinical trial for spinal cord injuries; AST-VAC2 is a non-patient-specific cancer immunotherapy derived from pluripotent stem cells for the treatment of non-small cell lung cancer; and AST-VAC1, a patient-specific cancer immunotherapy that has completed Phase II clinical trial for the treatment of acute myeloid leukemia. The company was formerly known as BioTime Acquisition Corporation and changed its name to Asterias Biotherapeutics, Inc. in March 2013. Asterias Biotherapeutics, Inc. was founded in 2012 and is headquartered in Fremont, California.
Read More
Asterias Biotherapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.52 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:AST
Previous SymbolNYSEMKT:AST
CUSIPN/A
CIKN/A
Phone+1-510-4563805

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$111,318.00
Next Earnings DateN/A
OptionableOptionable
$0.0020
0.00 (0.00 %)
(As of 07/10/2019)
30 days | 90 days | 365 days | Advanced Chart

Receive AST News and Ratings via Email

Sign-up to receive the latest news and ratings for AST and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Asterias Biotherapeutics (NYSEAMERICAN:AST) Frequently Asked Questions

How were Asterias Biotherapeutics' earnings last quarter?

Asterias Biotherapeutics Inc (NYSEAMERICAN:AST) issued its quarterly earnings data on Tuesday, March, 28th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by $0.01. The biotechnology company had revenue of $1.75 million for the quarter, compared to analysts' expectations of $2.81 million.
View Asterias Biotherapeutics' earnings history
.

Has Asterias Biotherapeutics been receiving favorable news coverage?

News coverage about AST stock has been trending extremely negative this week, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Asterias Biotherapeutics earned a media sentiment score of -4.1 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the immediate future.
View the latest news about Asterias Biotherapeutics
.

Who are some of Asterias Biotherapeutics' key competitors?

What other stocks do shareholders of Asterias Biotherapeutics own?

Who are Asterias Biotherapeutics' key executives?

Asterias Biotherapeutics' management team includes the following people:
  • Mr. Michael H. Mulroy, CEO, Pres & Director (Age 53)
  • Dr. Edward D. Wirth III, Chief Medical Officer (Age 54)
  • Dr. Katharine E. Spink, Consultant (Age 45)
  • Mr. Stephen L. Cartt, Advisor & Director (Age 56)
  • Mr. Ryan D. Chavez, CFO & Gen. Counsel (Age 43)

What is Asterias Biotherapeutics' stock symbol?

Asterias Biotherapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "AST."

How do I buy shares of Asterias Biotherapeutics?

Shares of AST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Asterias Biotherapeutics' stock price today?

One share of AST stock can currently be purchased for approximately $0.00.

How big of a company is Asterias Biotherapeutics?

Asterias Biotherapeutics has a market capitalization of $111,318.00.

What is Asterias Biotherapeutics' official website?

The official website for Asterias Biotherapeutics is asteriasbiotherapeutics.com.

How can I contact Asterias Biotherapeutics?

Asterias Biotherapeutics' mailing address is 6300 Dumbarton Cir, FREMONT, CA 94555-3644, United States. The biotechnology company can be reached via phone at +1-510-4563805.

This page was last updated on 8/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.